Carrier rate of zidovudine-resistant HIV-1: The impact of failing therapy on transmission of resistant strains

AIDS

Volumn 15, Issue 17, 2001, Pages 2293-2301

  Goudsmit, Jaap ^a   Jan Weverling, Gerrit Jan ^a   Van der Hoek, Lia ^a   De Ronde, Anthony ^a   Miedema, Frank ^a   Coutinho, Roel A ^a   Lange, Joep M A ^a   Boerlijst, Maarten C ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

HIV; Mathematical model; Resistance mutations; Transmission; Zidovudine

Indexed keywords

ZALCITABINE; ZIDOVUDINE;

ARTICLE; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MATHEMATICAL MODEL; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEQUENCE ANALYSIS; STRAIN DIFFERENCE; VIRUS GENE; VIRUS RESISTANCE; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARRIER STATE; COHORT STUDIES; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HOMOSEXUALITY, MALE; HUMANS; INCIDENCE; MALE; MODELS, GENETIC; MODELS, STATISTICAL; NETHERLANDS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT FAILURE; TREATMENT OUTCOME; VARIATION (GENETICS); VIRAL LOAD; ZIDOVUDINE;

EID: 0035941385     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200111230-00011     Document Type: Article

References (39)

1. Administration of 3′-azido-3′-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex
2. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial
3. Clinical pharmacokinetics of nucleoside antiretroviral agents
4. Nucleoside analogs: Similarities and differences
5. Effect of zidovudine on serum human immunodeficiency virus antigen levels in symptom-free subjects
6. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection
7. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT)
8. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects
9. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial
10. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter
11. Delta: A randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals
12. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres
13. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS Trial
14. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
15. Changing patterns of mortality across Europe in patients infected with HIV-1
16. Antiviral effect of double and triple drug combinations amongst HIV-infected adults: Lessons from the implementation of viral load-driven antiretroviral therapy
17. Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy
18. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy
19. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy
20. Antiretroviral drug resistance testing in adults with HIV infection: Implications for clinical management
21. Outcome and predictors of failure of highly active antiretroviral therapy: One-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons
22. Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients
23. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations
24. Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs
25. Rapid and simple method for purification of nucleic acids
26. Sensitive procedure for the amplification of HIV-1 RNA using a combined reverse-transcription and amplification reaction
27. Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants
28. Expression of human immunodeficiency virus antigen (HIV-Ag) in serum and cerebrospinal fluid during acute and chronic infection
29. Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy
30. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: Genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS Clinical Trials Group
31. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype
32. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy
33. Human immunodeficiency virus fitness in vivo: Calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase
34. Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus
35. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: Prospective multicentre study
36. A tale of two futures: HIV and antiretroviral therapy in San Francisco
37. Sexual risk behaviour relates to the virological and immunological improvements during highly active antiretroviral therapy in HIV-1 infection
38. Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro
39. Viral load and heterosexual transmission of human immunodeficiency virus type 1